Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Blood. 2009 Sep 24;114(13):2617-8. doi: 10.1182/blood-2009-01-198788. Epub 2009 Jul 29.

    The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma.

    Source

    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.

    Abstract

    The current definition of complete response in multiple myeloma includes a requirement for a bone marrow (BM) examination showing less than 5% plasma cells in addition to negative serum and urine immunofixation. There have been suggestions to eliminate the need for BM examinations when defining complete response. We evaluated 92 patients with multiple myeloma who achieved negative immunofixation in the serum and urine after therapy and found that 14% had BM plasma cells more than or equal to 5%. Adding a requirement for normalization of the serum-free light chain ratio to negative immunofixation studies did not negate the need for BM studies; 10% with a normal serum-free light chain ratio had BM plasma cells more than or equal to 5%. We also found that, on achieving immunofixation-negative status, patients with less than 5% plasma cells in the BM had improved overall survival compared with those with 5% or more BM plasma cells (6.2 years vs 2.3 years, respectively; P = .01).

    PMID:
    19641191
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2756122
    Free PMC Article

    Images from this publication.See all images (2)Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk